Teleflex Incorporated (TFX)
- Zacks
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
- GlobeNewswire
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift™ 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significa
- GlobeNewswire
Teleflex’s Climate Targets Validated by the Science Based Targets Initiative
Teleflex commits to reach net-zero greenhouse gas emissions across its value chain by 2050.WAYNE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced its near- and long-term climate change targets have been validated by the Science Based Targets initiative (SBTi). The announcement comes ahead of the company’s release of its 2023 Global Impact Report, which will be published in May 2024. Teleflex has respond
